3B Blackbio Dx (3BBLACKBIO) Stock Overview

Engages in the design, development, manufacturing, and commercialization of molecular diagnostic solutions for infectious diseases, oncology, human genetics and antimicrobial resistance in India. More details

3BBLACKBIO fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	3/6
Financial Health	6/6
Dividends	3/6

Rewards

Price-To-Earnings ratio (17.1x) is below the Indian market (23.9x)

Earnings grew by 22.8% over the past year

Risk Analysis

Earnings have declined by 6% per year over past 5 years

3BBLACKBIO Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW500,105 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

500,105 investors already sharing narratives

View all narratives

3B Blackbio Dx Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for 3B Blackbio Dx
Historical stock prices
Current Share Price	₹1,168.50
52 Week High	₹1,441.50
52 Week Low	₹1,085.00
Beta	0.42
1 Month Change	4.27%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-10.25%

Recent updates

Shareholder Returns

	3BBLACKBIO	IN Chemicals	IN Market
7D	-0.03%	2.8%	1.8%
1Y	n/a	-4.1%	-0.9%

Return vs Industry: Insufficient data to determine how 3BBLACKBIO performed against the Indian Chemicals industry.

Return vs Market: Insufficient data to determine how 3BBLACKBIO performed against the Indian Market.

Price Volatility

Is 3BBLACKBIO's price volatile compared to industry and market?
3BBLACKBIO volatility
3BBLACKBIO Average Weekly Movement	7.4%
Chemicals Industry Average Movement	6.3%
Market Average Movement	6.4%
10% most volatile stocks in IN Market	9.3%
10% least volatile stocks in IN Market	4.0%

Stable Share Price: 3BBLACKBIO has not had significant price volatility in the past 3 months compared to the Indian market.

Volatility Over Time: Insufficient data to determine 3BBLACKBIO's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1972	85	Dhirendra Dubey	3bblackbio.com

3B Blackbio Dx Limited engages in the design, development, manufacturing, and commercialization of molecular diagnostic solutions for infectious diseases, oncology, human genetics and antimicrobial resistance in India. The company offers qPCR-based and lateral flow assays rapid tests and Next Gen Sequencing -based molecular diagnostic kits for accurate and reliable testing on patient samples under the TRUPCR, TRUNGS, TRURAPID, brand for testing on patient samples to diagnostics labs. It also offers agrochemical products; technical support and training services.

3B Blackbio Dx Limited Fundamentals Summary

How do 3B Blackbio Dx's earnings and revenue compare to its market cap?
3BBLACKBIO fundamental statistics
Market cap	₹10.33b
Earnings (TTM)	₹585.86m
Revenue (TTM)	₹1.42b

17.1x

P/E Ratio

7.1x

P/S Ratio

Is 3BBLACKBIO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
3BBLACKBIO income statement (TTM)
Revenue	₹1.42b
Cost of Revenue	₹358.55m
Gross Profit	₹1.06b
Other Expenses	₹474.77m
Earnings	₹585.86m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	68.37
Gross Margin	74.74%
Net Profit Margin	41.28%
Debt/Equity Ratio	0.9%

How did 3BBLACKBIO perform over the long term?

See historical performance and comparison

Dividends

0.4%

Current Dividend Yield

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/07 13:24
End of Day Share Price	2026/07/07 00:00
Earnings	2026/03/31
Annual Earnings	2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

3B Blackbio Dx Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

3B Blackbio Dx LimitedNSEI:3BBLACKBIO Stock Report